Introduction {#S0001}
============

Gastric cancer is one of the most common cancers worldwide and the fourth most common cancer with high mortality in South Korea in 2015. Gastric cancer (GC) incidence remains high in Asian countries despite its global decrease over the past few years.[@CIT0001],[@CIT0002]

Long noncoding RNAs (lncRNAs) are defined as non-coding transcripts with lengths \> 200 nucleotides.[@CIT0003] In recent years, a number of studies have demonstrated that non-coding RNAs, such as lncRNAs, are implicated in cancer development through regulation of cancer-related gene expression, thus acting as oncogenes and tumor suppressors in several cancers.[@CIT0004] LncRNAs including H19 imprinted maternally expressed transcript (H19),[@CIT0005],[@CIT0006] HOX transcript antisense RNA (HOTAIR),[@CIT0007],[@CIT0008] colon cancer-associated transcript 2(CCAT2),[@CIT0009],[@CIT0010] Pvt1 oncogene (PVT1),[@CIT0011],[@CIT0012] and metastasis-associated lung adenocarcinoma transcript 1(MALAT1)[@CIT0013],[@CIT0014] have been reported as oncogenes that are upregulated in gastric cancer. However, lncRNAs including maternally expressed 3 (MEG 3)[@CIT0015],[@CIT0016] and growth arrest-specific 5 (GAS5)[@CIT0017] have demonstrated as tumor suppressors that were downregulated in gastric cancer. LncRNA highly up- have been demonstrated as tumor suppressors that are downregulated in gastric cancer. The lncRNA highly upregulated liver cancer (*HULC*) gene, located on chromosome 6p24.3, has a length of 1638 bp and comprises two exons and one intron. *HULC* has been reported as an oncogene that is upregulated in several cancers, including hepatocellular carcinoma (HCC),[@CIT0018] gastric cancer,[@CIT0019] pancreatic cancer,[@CIT0020] osteosarcoma,[@CIT0021] glioma[@CIT0022] and ovarian cancer.[@CIT0023] Additionally, recent studies have reported that genetic variations in *HULC* are associated with susceptibility to various cancers. For instance, in Chinese populations, Liu et al reported the association between HULC rs7763881 SNP and decreased HCC risk,[@CIT0024] and Kang et al reported the association between *HULC* rs7763881 SNP and decreased esophageal squamous cell carcinoma (ESCC) risk.[@CIT0025] In Egyptian populations, Shaker et al reported the association between *HULC* rs7763881 SNP and decreased colorectal cancer (CRC) risk,[@CIT0027] and Motawi et al reported the association between *HULC* rs7763881 SNP and decreased HCC risk.[@CIT0026] However, the association between *HULC* rs7763881 SNP and GC risk is not yet reported.

Based on previous study, we hypothesized *HULC* rs7763881 SNP may contribute to susceptibility to GC. Therefore, we investigated the association between *HULC* rs7763881 SNP and GC risk in a Korean population. We further evaluated the correlation of *HULC* rs7763881 SNP with clinical features, including age, gender, tumor differentiation, histological type, LNM, T classification, and tumor stage.

Patientss and Methods {#S0002}
=====================

Study Subjects {#S0002-S2001}
--------------

This study was approved and reviewed by the Ethics Committee of the institutional review board of Chungnam National University Hospital, and in compliance with the Declaration of Helsinki. A total of 459 GC subjects and 379 control subjects were enrolled. The blood samples used in this study were provided by the Chungnam National Hospital Biobank, a member of the National Biobank of Korea, which is supported and audited by the Ministry of Health and Welfare of Korea. All individuals enrolled in this study provided written informed consent for blood collection and use. GC patients were recruited from the outpatient clinic at the Chungnam National University Hospital and classified according to Lauren's classification.[@CIT0028] The subjects for the control group were randomly selected among healthy volunteers visiting the Chungnam National University Hospital medical center for their annual physical examinations; only individuals who had no history of cancer were included.

DNA Isolation and Genotyping {#S0002-S2002}
----------------------------

Genomic DNA was isolated from peripheral blood samples of all subjects using the QIAamp DNA Blood Mini Kit (Qiagen GmbH, Hilden, Germany), according to the manufacturer's instructions. *HULC* rs7763881 SNP was genotyped by the Applied Biosystems TaqMan SNP Genotyping Assay using predesigned primer/probe sets (C_29335152_10). PCR was performed using the StepOnePlus Real-time PCR System (Applied Biosystems) according to the following conditions: one cycle at 95 °C for 10 min; 45cycles at 92 °C for 15 s and 60 °C for 90 s.

Statistical Analysis {#S0002-S2003}
--------------------

Hardy Weinberg equilibrium (HWE) for each SNP in the control groups was estimated using the chi-square test. Differences in age and gender between the GC and control groups were calculated using the two-sided Pearson chi-square test and the Mann--Whitney *U*-test. Five genetic models, including codominant (CC or AC vs AA), dominant (AC+CC vs AA), recessive (CC vs AA+AC), additive CC vs AA), and allelic (C vs A) models, were used to analyze the associations. A binary logistic regression was used to estimate the GC risk according to odds ratios (ORs) and 95% confidence intervals (CIs). The association analysis was adjusted by age and sex, which were included in the model as covariates. All statistical analyses were performed using the SPSS (SPSS Inc., Chicago, IL, USA), version 20.0 for Windows. *P* \< 0.05 was considered statistically significant.

Results {#S0003}
=======

Characteristics of Study Subjects {#S0003-S2001}
---------------------------------

The characteristics of 459 GC and 379 control subjects are summarized in [Table 1](#T0001){ref-type="table"}. There were statistically significant differences in the age and gender distribution between the two groups (*P* \< 0.001 and *P* \< 0.001, respectively). The mean age was 65.2±10.6 years for GC patients and 56.1±10.9 years for the controls. The percentage of GC male subjects (70.2%) was higher than that of females (29.8%), whereas the number of female control subjects (68.1%) was higher than that of males (31.9%). The GC group consisted of 48.4% well-differentiated GC, 56.2% intestinal-type, 51.0% T1, 62.3% lymph node metastasis, and 59.9% stage I tumor cases.Table 1Demographic and Clinical Features of the Gastric Cancer Group and the Control GroupVariablesGastric CancersControls*P*N (%)N (%)Age (years) (mean±SD)459 (65.2±10.6)379 (56.1±10.9)\<0.001\* \<60197 (42.9)195 (51.5)0.014\*\* ≥60262 (57.1)184 (48.5)Gender (%) Male322 (70.2)121 (31.9)\<0.001\*\* Female137 (29.8)258 (68.1)Tumor Differentiation (%) Differentiated222 (48.4) Undifferentiated196 (42.7) Missing41 (8.9)Histological Type (%) Intestinal258 (56.2) Diffuse148 (32.2) Mixed53 (11.6)T Classification (%) T1234 (51.0) T267 (14.6) T316 (3.5) T4142 (30.9)Lymph Node Metastasis (%) Negative286 (62.3) Positive173 (37.7)Tumor Stage (%) I (A+B)275 (59.9) II (A+B)55 (12.0) III (A+B+C)129 (28.1)[^2][^3]

Association of SNP and GC Risk {#S0003-S2002}
------------------------------

We genotyped rs7763881 SNP in *HULC*, which has been previously associated with cancer risk. The genotype distribution of rs7763881 SNP, both among the GC group and the control group, was in accordance with HWE (*P* = 0.998 and *P* = 0.373, respectively). We applied five genetic models to assess the possible association between the rs7763881 SNP and GC risk. However, no significant association between rs7763881 SNP and GC risk was observed ([Table 2](#T0002){ref-type="table"}).Table 2Genotype and Allele Frequencies for *HULC* rs7763881 Polymorphism Among Subjects and Their Association with GC RiskGenotypeCONGC vs CONN (%)N (%)AOR (95% CI)^a^*P*^a^rs7763881Codominant AA130 (34.3)142 (31.0)1 AC195 (51.5)226 (49.2)1.05 (0.75--1.46)0.794 CC54 (14.2)91 (19.8)1.50 (0.96--2.34)0.077Dominant AA130 (34.3)142 (31.0)1 AC+CC249 (65.7)317 (69.0)1.14 (0.84--1.57)0.404Recessive AA+AC325 (85.8)368 (80.2)1 CC54 (14.2)91 (19.8)1.46 (0.98--2.17)0.064Additive AA130 (70.7)142 (60.9)1 CC54 (29.3)91 (39.1)1.51 (0.97--2.37)0.071Alleles A455 (60)510 (55.6)1 C303 (40)408 (44.4)1.18 (0.96--1.46)0.119 HWE0.3730.998[^4][^5]

Stratified Analysis for rs7763881 SNP {#S0003-S2003}
-------------------------------------

Further, we performed stratified analyses to evaluate the possible association between rs7763881 SNP and GC risk based on various disease characteristics, including age, gender, tumor differentiation, histological type, LNM, T classification, and tumor stage. The results are shown in [Table 3](#T0003){ref-type="table"}. After adjusting age and gender, the rs7763881 recessive model (CC) showed a significant association with an increased GC risk in the undifferentiated (OR = 1.85, 95% CI = 1.17--2.94, *P* = 0.009), diffuse-type GC (OR = 1.72, 95% CI = 1.05--2.82, *P* = 0.033), LNM-positive (OR = 2.02, 95% CI = 1.24--3.27, *P* = 0.004), T3/T4 (OR = 1.75, 95% CI = 1.05--2.91, *P* = 0.032), and tumor stage III (OR = 2.01, 95% CI = 1.17--3.45, *P* = 0.011) subgroups, when compared to the rs7763881 combined genotypes (AA+AC). Furthermore, the rs7763881 additive model (CC) indicated a significantly higher GC risk than rs7763881 AA genotype in the undifferentiated (OR = 1.96, 95% CI = 1.15--3.32, *P* = 0.013), diffuse-type GC (OR = 2.08, 95% CI = 1.23--3.52, *P* = 0.004), and LNM-positive (OR = 2.00, 95% CI = 1.14--3.49, *P* = 0.016) subgroups ([Table 3](#T0003){ref-type="table"}).Table 3Stratified Analysis for *HULC* rs7763881 Polymorphism in GC Patients and ControlsVariablesRecessive (CC/AA+AC)Additive (CC/AA)GCCONOR (95% CI)^a^*P*^a^GCCONOR (95% CI)\**P*^a^Age (years) \<6044/15429/1661.43 (0.79--2.60)0.23544/5829/731.70 (0.86--3.34)0.125 ≥6047/21525/1591.40 (0.79--2.48)0.24347/8425/571.27 (0.68--2.39)0.449Sex Male67/25517/1041.60 (0.89--2.85)1.11467/9717/421.70 (0.89--3.24)1.06 Female24/11337/2211.36 (0.76--2.41)0.30024/4537/881.39 (0.72--2.66)0.327Tumor D﻿ifferentiation Differentiated54/32524/3251.13 (0.67--1.91)0.63636/7624/1301.11 (0.62--1.98)0.736 Undifferentiated36/18624/3251.85 (1.17--2.94)**0.009**47/5624/1301.96 (1.15--3.32)**0.013**Histological Type Intestinal43/21524/3251.19 (0.73--1.95)0.49443/8924/1301.13 (0.65--1.95)0.669 Diffuse35/11324/3251.72 (1.05--2.82)**0.033**35/3824/1302.08 (1.23--3.52)**0.004**Lymph Node Metastasis Negative47/23924/3251.22 (0.76--1.44)0.41047/9124/1301.28 (0.77--2.16)0.344 Positive44/12924/3252.02 (1.24--3.27)**0.004**44/5124/1302.00 (1.14--3.49)**0.016**T Classification T1/T256/24524/3251.41 (0.90--2.21)0.13556/8924/1301.62 (0.97--2.71)0.065 T3/T435/12324/3251.75 (1.05--2.91)**0.032**35/5324/1301.53 (0.87--2.70)0.144Tumor Stage I (A+B)/II (A+B+C)61/26924/3251.36 (0.87--2.10)0.17461/9824/1301.53 (0.93--2.52)0.093 III (A+B+C)30/9424/3252.01 (1.17--3.45)**0.011**30/4424/1301.69 (0.93--3.09)0.086[^6][^7]

Discussion {#S0004}
==========

In recent years, a number of studies have reported the association of lncRNA *HULC* polymorphisms with decreased risk of HCC, ESCC, and CRC.[@CIT0024]--[@CIT0027] In this case-control study, we first investigated the association between *HULC* rs7763881 SNP and GC risk but did not observe a significant association between them. However, stratified analysis by age, gender, tumor differentiation, histological type, LNM, T classification, and tumor stage revealed statistically significant association between *HULC* rs7763881 CC genotype and increased GC risk of the undifferentiated, diffuse-type, LNM-positive, T3/T4, and tumor stage III groups. Till date, contradictory to our results, previous studies have reported the relationship between rs7763881 AC or AC+CC genotype with the decreased risk of several cancers, including HBV carried HCC, ESCC, and CRC.[@CIT0024]--[@CIT0027] Through stratification analysis. Of Chinese populations, Kang et al showed that rs7763881 AC genotype is significantly associated with decreased ESCC risk in male patients compared to rs7763881 AA genotype. Moreover, stratification analysis of Egyptian populations by Shaker et al suggested that rs7763881 AC genotype is significantly associated with decreased CRC risk in younger patients compared to rs7763881 AA genotype.[@CIT0025],[@CIT0027] However, we did not observe the association of rs7763881 genotypes with GC risk in stratified subgroups by age and gender. To evaluate the possible clinical applications of lncRNA as a GC diagnosis biomarker, recent studies have assessed the correlation between lncRNA expression levels and clinical features such as tumor differentiation, histological type, LNM, T classification, and tumor stage in GC and reported their association. Moreover, it has recently been reported that lncRNAs play a pivotal role in development and progression of human cancer. In GC, overexpression of lncRNAs is correlated with clinical features of GC patients such as tumor differentiation, LNM, and tumor stage. Li et al showed an association between enhanced expression of H19 and LN number (N2-3) and tumor stage (III--IV) of GC.[@CIT0005] Zhang et al and Liu et al reported the relationship between HOTAIR overexpression and poor differentiation, LNM, and advanced tumor stage (III--IV).[@CIT0008],[@CIT0029] Sun et al showed an association between decreased expression of MEG3 and GAS5 and TNM stage and LNM of GC.[@CIT0015],[@CIT0017] Zhao et al revealed the relationship between increased expression of HULC and LNM present and GC tumor stage (III--IV).[@CIT0019] Ding et al observed a positive correlation between increased expression of PVT1 and LNM of GC.[@CIT0030] Additionally, Hong et al showed an association between lncRNA *PRNCR1* SNPs and risk of GC in LNM-positive and tumor stage III subgroups.[@CIT0031] In our data, although we did not investigate the correlation between *HULC* rs7763881 CC genotype and *HULC* gene expression, we found that *HULC* rs7763881 CC genotype in the dominant and additive genetic model was associated with a higher risk for GC of undifferentiated, diffuse-type, LNM-positive, T3/T4, and tumor stage III groups.

There were a few limitations of this case-control study. First, the sample size is relatively small for a stratified analysis, leading to the reduction of the statistical power. Second, we failed to investigate the association between the genetic factors and other clinical features such as *Helicobacter pylori* infection, smoking, drinking, and diet, owing to lack of these data from the GC and control groups. Fourth, large prospective studies are needed to validate our results in different ethnic groups.

Conclusions {#S0005}
===========

In conclusion, based on previous studies and our results, we suggest that *HULC* rs7763881 CC genotype may contribute to GC development by affecting HULC as an oncogene. Further studies are required to validate our findings in large populations and different ethnic groups to clarify whether *HULC* rs7763881 CC increases GC risk by altering *HULC* gene expression.

This work was supported by research fund of Chungnam National University, by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIP) (NRF-2016R1D1A3B03936067), and by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2017R1D1A1B04033515, NRF-2018R1D1A1B07050285, and NRF-2019R1F1A1063469).

Abbreviations {#S0006}
=============

AOR, adjusted odds ratio; CI, confidence interval; CON, control; CCAT2, colon cancer-associated transcript 2; CRC, colorectal cancer; ESCC, esophageal squamous cell carcinoma; GAS5, growth arrest-specific 5; GC, Gastric cancer; H19, imprinted maternally expressed transcript; HCC, hepatocellular carcinoma; HOTAIR, HOX transcript antisense RNA; HULC, highly upregulated in liver cancer; HWE, Hardy Weinberg equilibrium; LncRNAs, long non-coding RNAs; LNM, lymph node metastasis; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; MEG 3, maternally expressed 3; PVT1, Pvt1 oncogene; SD, standard deviation; SNPs, single-nucleotide polymorphisms.

Disclosure {#S0007}
==========

The authors have declared that no competing interest exists in this work.

[^1]: These authors contributed equally to this work

[^2]: **Notes:** \*Mann--Whitney *U*-test. \*\*Two-sided Pearson chi-square test.

[^3]: **Abbreviation:** SD, standard deviation.

[^4]: **Note:** ^a^Adjusted for age and gender.

[^5]: **Abbreviations:** CON, control; GC, gastric cancer; AOR, adjusted odds ratio; CI, confidence interval; HWE, Hardy--Weinberg equilibrium.

[^6]: **Notes:** ^a^Adjusted by age and gender. The significant results are in bold.

[^7]: **Abbreviations:** GC, gastric cancer; CON, controls; OR, odds ratio; CI, confidence interval.
